AMG 557 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 3 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01683695 (ClinicalTrials.gov) | June 2012 | 14/3/2012 | Safety Study of AMG 557 in Subjects With Lupus Arthritis | A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis | Lupus Arthritis, Systemic Lupus Erythematosus | Drug: AMG 557;Drug: Matching Placebo | Amgen | NULL | Completed | 18 Years | 65 Years | All | 20 | Phase 1 | United States;Australia;Denmark;France;Germany;Malaysia;Taiwan;United Kingdom;Singapore |
| 2 | NCT00774943 (ClinicalTrials.gov) | December 2008 | 16/10/2008 | A Study of AMG 557 in Adults With Systemic Lupus Erythematosus | A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: AMG 557 | Amgen | NULL | Completed | 18 Years | 70 Years | Both | 58 | Phase 1 | United States;Canada |
| 3 | NCT02391259 (ClinicalTrials.gov) | November 2006 | 6/1/2015 | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus | Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: AMG 557;Drug: Placebo | Amgen | NULL | Completed | 18 Years | 70 Years | Both | 57 | Phase 1 | United States;United Kingdom |